Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Test your medicine knowledge: 59-year-old man with gout

mksap
Conditions
November 7, 2015
Share
Tweet
Share

Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.

A 59-year-old man is evaluated for a 6-month history of gout. He was doing well on colchicine and allopurinol but developed hypersensitivity to allopurinol, which resolved with cessation of the agent. He then began to have more frequent gout flares; two flares occurred in the past month and were treated with prednisone. History is also significant for hypertension, chronic kidney disease, and dyslipidemia. Current medications are colchicine, lisinopril, metoprolol, and simvastatin.

On physical examination, temperature is 37.2 °C (98.9 °F), blood pressure is 142/86 mm Hg, pulse rate is 64/min, and respiration rate is 12/min. BMI is 30. The remainder of the examination is normal.

Laboratory studies reveal a serum creatinine level of 2.3 mg/dL (203.3 µmol/L), a serum urate level of 9.2 mg/dL (0.54 mmol/L), and normal liver chemistry studies; estimated glomerular filtration rate is 48 mL/min/1.73 m2.

Which of the following is the most appropriate next step in management?

A: Discontinue colchicine
B: Start febuxostat
C: Start pegloticase
D: Start probenecid

MKSAP Answer and Critique

The correct answer is B: Start febuxostat.

Febuxostat is indicated for this patient with frequent gout attacks. He had been taking allopurinol, a first-line agent for serum urate reduction in patients with gout. Urate-lowering therapy is indicated for patients with gout who experience repeated attacks (≥2 per year), have one attack in the setting of chronic kidney disease (CKD) of stage 2 or worse, have tophaceous deposits found on examination or imaging, or have a history of urolithiasis. This patient developed an adverse reaction to allopurinol but still needs urate-lowing therapy. Febuxostat is a newer non-purine, non-competitive xanthine oxidase inhibitor, which is a viable alternative to allopurinol. It can be used in patients with mild to moderate CKD and is safe to try after an adverse reaction or failure of allopurinol.

Anti-inflammatory prophylaxis to prevent gout attacks is recommended when urate-lowering therapy is initiated because of the paradoxical increased risk of acute gout attacks when serum urate levels are rapidly decreased by medication. Prophylaxis should be continued in the presence of any active disease (tophi or flares). Colchicine is a first-line option for gout prophylaxis and should not be discontinued in this patient who requires flare prophylaxis during urate-lowering therapy.

Pegloticase is an intravenous synthetic uricase replacement approved for treatment-failure gout. Pegloticase is immunogenic, and the development of antibodies eventually occurs in most patients taking the drug, which leads to reduced effectiveness and increases the risk of hypersensitivity reactions.

The uricosuric drugs probenecid and sulfinpyrazone promote kidney clearance of uric acid by inhibiting urate-anion exchangers in the proximal tubule responsible for urate reabsorption. These agents are relatively contraindicated in patients with impaired kidney function or those at risk for kidney stones.

Key Point

  • In patients with gout who require urate-lowering therapy, febuxostat is a viable alternative for those who have an adverse reaction to allopurinol.

This content is excerpted from MKSAP 17 with permission from the American College of Physicians (ACP). Use is restricted in the same manner as that defined in the MKSAP 17 Digital license agreement. This material should never be used as a substitute for clinical judgment and does not represent an official position of ACP. All content is licensed to KevinMD.com on an “AS IS” basis without any warranty of any nature. The publisher, ACP, shall not be liable for any damage or loss of any kind arising out of or resulting from use of content, regardless of whether such liability is based in tort, contract or otherwise.

Prev

Physician, heal thyself. A reflection on physician self-care.

November 6, 2015 Kevin 3
…
Next

What does an older cardiologist worry about today?

November 7, 2015 Kevin 2
…

ADVERTISEMENT

Tagged as: Rheumatology

Post navigation

< Previous Post
Physician, heal thyself. A reflection on physician self-care.
Next Post >
What does an older cardiologist worry about today?

ADVERTISEMENT

More by mksap

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 26-year-old man with back pain

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 36-year-old man with abdominal cramping, diarrhea, malaise, and nausea

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 52-year-old woman with osteoarthritis of the right hip

    mksap

Related Posts

  • How social media can advance humanism in medicine

    Pooja Lakshmin, MD
  • The difference between learning medicine and doing medicine

    Steven Zhang, MD
  • KevinMD at the Richmond Academy of Medicine

    Kevin Pho, MD
  • Medicine won’t keep you warm at night

    Anonymous
  • Delivering unpalatable truths in medicine

    Samantha Cheng
  • Merging the wisdom of pain medicine and addiction medicine to optimize outcomes

    Julie Craig, MD

More in Conditions

  • How early care saved my life from silent kidney disease

    Charlie Cloninger
  • Why GLP‑1 drugs should be covered beyond weight loss

    Rodney Lenfant
  • When recurrent UTIs might actually be bladder cancer

    Fara Bellows, MD
  • How chronic stress harms the heart in minority communities

    Monzur Morshed, MD and Kaysan Morshed
  • Could antibiotics beat heart disease where statins failed?

    Larry Kaskel, MD
  • Universities must tap endowments to sustain biomedical research

    Adeel Khan, MD
  • Most Popular

  • Past Week

    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • When life makes you depend on Depends

      Francisco M. Torres, MD | Physician
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How early care saved my life from silent kidney disease

      Charlie Cloninger | Conditions
    • How functional medicine fills the gaps left by conventional care

      Sally Daganzo, MD | Physician
    • A psychiatrist’s 20-year journey with ketamine

      Muhamad Aly Rifai, MD | Meds
    • How racism and policy failures shape reproductive health in America

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Education
    • Why GLP‑1 drugs should be covered beyond weight loss

      Rodney Lenfant | Conditions
    • How drug companies profit by inventing diseases

      Martha Rosenberg | Meds

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • When life makes you depend on Depends

      Francisco M. Torres, MD | Physician
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How early care saved my life from silent kidney disease

      Charlie Cloninger | Conditions
    • How functional medicine fills the gaps left by conventional care

      Sally Daganzo, MD | Physician
    • A psychiatrist’s 20-year journey with ketamine

      Muhamad Aly Rifai, MD | Meds
    • How racism and policy failures shape reproductive health in America

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Education
    • Why GLP‑1 drugs should be covered beyond weight loss

      Rodney Lenfant | Conditions
    • How drug companies profit by inventing diseases

      Martha Rosenberg | Meds

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...